Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Heron Therapeutics is a commercial-stage biotechnology company focused on pain management products, primarily ZYNRELEF (bupivacaine/meloxicam) for post-surgical pain and CINVANTI (aprepitant injectable) for chemotherapy-induced nausea. The company operates in the competitive specialty pharmaceutical market with limited product diversification, facing significant commercial execution risk as it attempts to scale revenue from its two marketed products while managing a highly leveraged balance sheet.
Heron generates revenue through direct sales of proprietary formulations to hospitals and surgical centers. ZYNRELEF competes against generic local anesthetics and opioids by offering extended-release pain control (up to 72 hours) that may reduce opioid consumption and hospital costs. CINVANTI competes in the established antiemetic market with a differentiated IV formulation. Pricing power is moderate given hospital formulary dynamics and competitive alternatives. The company relies on specialty sales representatives targeting high-volume surgical centers and oncology practices. Gross margins are strong at 73% reflecting low manufacturing costs relative to pricing, but the company faces significant SG&A burden to support commercial infrastructure.
ZYNRELEF quarterly prescription volume trends and hospital formulary adoption rates across soft tissue and orthopedic procedures
Commercial execution updates including sales force productivity, market penetration in ambulatory surgical centers versus hospital outpatient departments
Clinical data releases or label expansion opportunities for ZYNRELEF in additional surgical procedures (orthopedic, spine)
Cash runway visibility and financing needs given negative operating cash flow and high debt/equity ratio of 9.44x
Competitive dynamics in post-surgical pain management including generic competition and alternative non-opioid therapies
Limited product diversification with revenue concentrated in two products, creating binary risk if either faces competitive or regulatory challenges
Shift toward value-based care and hospital cost containment pressures may limit adoption of premium-priced specialty pharmaceuticals versus generic alternatives
Regulatory risk including potential FDA safety reviews, manufacturing compliance issues, or label restrictions that could impact commercial viability
Patent expiration risk for ZYNRELEF and CINVANTI formulations could enable generic competition in outer years
Intense competition in post-surgical pain management from established generic local anesthetics, multimodal pain protocols, and emerging non-opioid alternatives from larger pharmaceutical companies
CINVANTI faces competition from generic aprepitant oral formulations and other NK1 receptor antagonists with established market share
Limited resources to compete against well-capitalized pharmaceutical companies with broader pain management portfolios and larger sales forces
Extremely high debt/equity ratio of 9.44x creates financial fragility and potential covenant breach risk if revenue targets are missed
Negative operating cash flow and free cash flow require ongoing capital raises, creating dilution risk for equity holders
Current ratio of 2.56x provides some near-term liquidity buffer, but cash burn rate could necessitate financing within 12-18 months if profitability is not achieved
Potential going concern risk if the company cannot achieve sustained profitability or secure additional financing on acceptable terms
moderate - Elective surgical volumes, which drive ZYNRELEF demand, exhibit moderate sensitivity to economic conditions as patients may defer non-urgent procedures during recessions due to cost concerns or reduced insurance coverage. However, oncology procedures driving CINVANTI demand are largely non-discretionary. Hospital capital budgets and formulary decisions can tighten during economic downturns, potentially slowing new product adoption. The company's revenue base is more dependent on healthcare utilization patterns than broad GDP growth.
Rising interest rates create multiple headwinds: (1) increased debt service costs on the company's substantial debt load (9.44x debt/equity), directly pressuring already negative operating cash flow; (2) higher discount rates compress valuation multiples for unprofitable biotech companies, particularly those requiring future financing; (3) potential refinancing risk if debt matures in high-rate environment. The company's negative free cash flow makes it vulnerable to tightening financial conditions.
High credit exposure given the company's unprofitable operations, negative operating cash flow of approximately $5M TTM, and elevated leverage ratio. Access to capital markets for potential equity or debt financing is critical for funding operations until profitability is achieved. Tightening credit conditions or risk-off sentiment in biotech could impair the company's ability to raise capital on favorable terms, creating existential risk if cash reserves deplete. High-yield credit spreads are a key indicator of financing availability for speculative-grade healthcare companies.
speculative growth - The stock attracts high-risk tolerance investors seeking asymmetric upside from successful commercial execution of ZYNRELEF in the large post-surgical pain market. The combination of small market cap ($200M), high leverage, negative cash flow, and binary commercial outcomes creates venture capital-like risk/reward profile. Not suitable for value or income investors given lack of profitability, dividends, and balance sheet stress. Recent 88.9% EPS growth reflects improvement from deeply negative baseline rather than sustainable profitability.
high - Micro-cap biotech with limited product portfolio, unprofitable operations, and high leverage exhibits elevated volatility. Stock performance shows -29.7% one-year return with significant drawdown risk. Clinical data releases, quarterly earnings surprises, financing announcements, and sector sentiment shifts drive sharp price movements. Beta likely exceeds 1.5x relative to broader market.
